Gain Therapeutics Stock Performance
| GANX Stock | USD 3.18 0.02 0.63% |
The company retains a Market Volatility (i.e., Beta) of 2.17, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Gain Therapeutics will likely underperform. Gain Therapeutics right now retains a risk of 4.0%. Please check out Gain Therapeutics value at risk, as well as the relationship between the rate of daily change and relative strength index , to decide if Gain Therapeutics will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Gain Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Gain Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.63 | Five Day Return (2.45) | Year To Date Return (12.40) | Ten Year Return (71.61) | All Time Return (71.61) |
1 | Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule... | 02/27/2024 |
2 | EXCLUSIVE Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinsons Disease | 03/05/2024 |
3 | Gain Therapeutics to Present at Public Ventures Discovery Day | 03/15/2024 |
4 | Acquisition by Alder Matthias of 370000 shares of Gain Therapeutics at 4.37 subject to Rule 16b-3 | 03/21/2024 |
5 | Disposition of 637 shares by Alder Matthias of Gain Therapeutics subject to Rule 16b-3 | 03/26/2024 |
6 | Acquisition by Riley Jeffrey Scott of 30000 shares of Gain Therapeutics at 3.859 subject to Rule 16b-3 | 03/28/2024 |
7 | Gain Therapeutics director buys 115k in company stock | 04/01/2024 |
8 | Brokers Issue Forecasts for Gain Therapeutics, Inc.s Q1 2024 Earnings - Defense World | 04/03/2024 |
9 | Disposition of 18750 shares by Alder Matthias of Gain Therapeutics subject to Rule 16b-3 | 04/05/2024 |
10 | Acquisition by Mack Gene of 200000 shares of Gain Therapeutics at 3.56 subject to Rule 16b-3 | 04/08/2024 |
11 | Heres Why Gain Therapeutics Could be Great Choice for a Bottom Fisher | 04/17/2024 |
| Begin Period Cash Flow | 7.3 M |
Gain |
Gain Therapeutics Relative Risk vs. Return Landscape
If you would invest 333.00 in Gain Therapeutics on January 19, 2024 and sell it today you would lose (15.00) from holding Gain Therapeutics or give up 4.5% of portfolio value over 90 days. Gain Therapeutics is currently generating 0.006% in daily expected returns and assumes 4.0025% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Gain, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Gain Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gain Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gain Therapeutics, and traders can use it to determine the average amount a Gain Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0015
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GANX |
Estimated Market Risk
| 4.0 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Gain Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gain Therapeutics by adding Gain Therapeutics to a well-diversified portfolio.
Gain Therapeutics Fundamentals Growth
Gain Stock prices reflect investors' perceptions of the future prospects and financial health of Gain Therapeutics, and Gain Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gain Stock performance.
| Return On Equity | -1.42 | ||||
| Return On Asset | -0.65 | ||||
| Operating Margin | (403.37) % | ||||
| Current Valuation | 35.49 M | ||||
| Shares Outstanding | 16.22 M | ||||
| Price To Book | 4.00 X | ||||
| Price To Sales | 925.92 X | ||||
| Revenue | 55.18 K | ||||
| Gross Profit | (7.66 M) | ||||
| EBITDA | (22.17 M) | ||||
| Net Income | (22.27 M) | ||||
| Cash And Equivalents | 24.25 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 7.58 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (18.87 M) | ||||
| Earnings Per Share | (1.71) X | ||||
| Market Capitalization | 51.25 M | ||||
| Total Asset | 18.61 M | ||||
| Retained Earnings | (60.78 M) | ||||
| Working Capital | 12.83 M | ||||
About Gain Therapeutics Performance
To evaluate Gain Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Gain Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Gain Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Gain Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Gain's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 197.37 | 175.44 | |
| Return On Tangible Assets | (1.21) | (1.27) | |
| Return On Capital Employed | (1.63) | (1.55) | |
| Return On Assets | (1.20) | (1.26) | |
| Return On Equity | (1.77) | (1.68) |
Things to note about Gain Therapeutics performance evaluation
Checking the ongoing alerts about Gain Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gain Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gain Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 55.18 K. Net Loss for the year was (22.27 M) with loss before overhead, payroll, taxes, and interest of (7.66 M). | |
| Gain Therapeutics currently holds about 24.25 M in cash with (18.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: Heres Why Gain Therapeutics Could be Great Choice for a Bottom Fisher |
- Analyzing Gain Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gain Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Gain Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gain Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gain Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gain Therapeutics' stock. These opinions can provide insight into Gain Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Gain Stock analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Gain Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. If investors know Gain will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gain Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.004 | Quarterly Revenue Growth (1.00) | Return On Assets (0.65) | Return On Equity (1.42) |
The market value of Gain Therapeutics is measured differently than its book value, which is the value of Gain that is recorded on the company's balance sheet. Investors also form their own opinion of Gain Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gain Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gain Therapeutics' market value can be influenced by many factors that don't directly affect Gain Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gain Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.